Home > Insider Trading > Filing (0001104659-24-101773)

Filing Details

Accession Number:: 0001104659-24-101773
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-09-20 18:34:18
Reporting Period:: 2024-09-18

Accepted Time:: 2024-09-20 18:34:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1953926	Zenas Biopharma Inc.	ZBIO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1228865	Jr O Leon Moulder	C/O Zenas Biopharma, Inc. 1000 Winter Street, Suite 1200 Waltham MA 02451	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-09-18	10,000	$17.91	1,662,039	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2024-09-19	5,000	$17.89	1,667,039	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2024-09-20	2,367	$17.88	1,669,406	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2024-09-20	2,633	$18.97	1,672,039	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	161,155	Direct

Footnotes

The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.50 to $18.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.64 to $18.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $17.70 to $18.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $18.35 to $19.24, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.